Pharmacological protection from radiation ± cisplatin-induced oral mucositis

International Journal of Radiation Oncology Biology Physics

Volumn 83, Issue 4, 2012, Pages 1284-1290

  Cotrim, Ana P ^a   Yoshikawa, Masanobu ^a,c   Sunshine, Abraham N ^a   Zheng, Changyu ^a   Sowers, Anastasia L ^b   Thetford, Angela D ^b   Cook, John A ^b   Mitchell, James B ^b   Baum, Bruce J ^a  

^a NATIONAL INSTITUTE OF DENTAL AND CRANIOFACIAL RESEARCH   (United States)

^b NATIONAL CANCER INSTITUTE   (United States)

^c TOKAI UNIVERSITY SCHOOL OF MEDICINE   (Japan)

Author keywords

Chemoradiation; D methionine; Oral mucositis; Side effects; Tempol

Indexed keywords

CHEMORADIATION; D-METHIONINE; ORAL MUCOSITIS; SIDE EFFECT; TEMPOL;

AMINO ACIDS; CHEMORADIOTHERAPY; CHEMOTHERAPY; DERMATOLOGY; DISEASES; IONIZING RADIATION; MAMMALS; PLATINUM COMPOUNDS;

RADIATION PROTECTION;

CISPLATIN; METHIONINE; TEMPOL; TOLONIUM CHLORIDE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CANCER CHEMOTHERAPY; CANCER RADIOTHERAPY; CONTROLLED STUDY; DRUG EFFICACY; FEEDING; FEMALE; HEAD AND NECK SQUAMOUS CELL CARCINOMA; IONIZING RADIATION; IRRADIATION; LINGUAL ULCER; MOUSE; MOUTH ULCER; NONHUMAN; ORAL MUCOSITIS; PRIORITY JOURNAL; RADIATION DOSE FRACTIONATION; THICKNESS; TONGUE;

ANIMALS; CHEMORADIOTHERAPY; CISPLATIN; CYCLIC N-OXIDES; FEMALE; METHIONINE; MICE; MICE, INBRED C3H; RADIATION INJURIES, EXPERIMENTAL; RADIATION-PROTECTIVE AGENTS; RADIATION-SENSITIZING AGENTS; SPIN LABELS; STOMATITIS;

EID: 84862671001     PISSN: 03603016     EISSN: 1879355X     Source Type: Journal    
DOI: 10.1016/j.ijrobp.2011.09.026     Document Type: Article

References (21)

1. Sonis ST. Mucositis: The impact, biology and therapeutic opportunities of oral mucositis. Oral Oncol 2009;45:1015-1020.
2. Epstein JB, Beaumont JL, Gwede CK, et al. Longitudinal evaluation of the oral mucositis weekly questionnaire-head and neck cancer, a patient-reported outcomes questionnaire. Cancer 2007;109: 1914-1922.
3. Elting LS, Keefe DM, Sonis ST, et al. Patient-reported measurements of oral mucositis in head and neck cancer patients treated with radiotherapy with and without chemotherapy. Cancer 2008;113: 2704-2713.
4. Nonzee NJ, Dandade NA, Markossian T, et al. Evaluating the supportive care costs of severe radiochemotherapy-induced mucositis and pharyngitis. Cancer 2008;113:1446-1452.
5. Murphy BA, Beaumont JL, Isitt J, et al. Mucositis-related morbidity and resource utilization in head and neck cancer patients receiving radiation therapy with or without chemotherapy. J Pain Symptom Manage 2009;38:522-532.
6. Sonis ST. Efficacy of palifermin (keratinocyte growth factor-1) in the amelioration of oral mucositis. Core Evidence 2009;4:199-205.
7. Vuyyuri SB, Hamstra DA, Khanna D, et al. Evaluation of D-methionine as a novel oral radiation protector for prevention of mucositis. Clin Cancer Res 2008;14:2161-2170.
8. Hamstra DA, Eisbruch A, Naidu MUR, et al. Pharmacokinetic analysis and phase 1 study of MRX-1024 in patients treated with radiation therapy with or without Cisplatinum for head and neck cancer. Clin Cancer Res 2010;16:2666-2676.
9. Zheng C, Cotrim AP, Sunshine AN, et al. Prevention of radiation-induced oral mucositis after adenoviral vector-mediated transfer of the keratinocyte growth factor cDNA to mouse submandibular glands. Clin Cancer Res 2009;15:4641-4646.
10. Mitchell JB, DeGraff W, Kaufman D, et al. Inhibition of oxygen-dependent radiation-induced damage by the nitroxide mimic, Tempol. Arch Biochem Biophys 1991;289:62-70.
11. Citrin D, Cotrim AP, Hyodo F, et al. Radioprotectors and mitigators of radiation induced normal tissue injury. Oncologist 2010;15: 360-371.
12. Cotrim AP, Hyodo F, Matsumoto K-I, et al. Differential radiation protection of salivary glands versus tumor by Tempol with accompanying tissue assessment of Tempol by magnetic resonance imaging. Clin Cancer Res 2007;13:4928-4933.
13. Bevington PR. Data Reduction and Error Analysis for the Physical Sciences. New York, NY: McGraw-Hill; 1969.
14. Snedecor GW, Cochran WG. Statistical Methods. Ames, IA: The Iowa State University Press; 1980.
15. Mehanna H, West CML, Nutting C, et al. Head and neck cancer - part 2: Treatment and prognostic factors. Br Med J 2010;41:721-725.
16. Cotrim AP, Sowers AL, Lodde BM, et al. Kinetics of Tempol for prevention of xerostomia following head and neck irradiation in a mouse model. Clin Cancer Res 2005;11:7564-7568.
17. Spielberger R, Stiff P, BensingerW, et al. Palifermin for oral mucositis after intensive therapy for hematologic cancers. N Engl J Med 2004; 351:2590-2598.
18. Buentzel J, Micke O, Adamietz IA, et al. Intravenous amifostine during chemoradiotherapy for head-and-neck cancer: A randomized placebo-controlled phase III study. Int J Radiat Oncol Biol Phys 2006; 64:684-691.
19. Hahn SM, Sullivan FJ, DeLuca AM, et al. Evaluation of Tempol radioprotection in a murine tumor model. Free Radic Biol Med 1997; 2:1211-1216.
20. Metz JM, Smith D, Mick R, et al. A phase I study of topical Tempol for the prevention of alopecia induced by whole brain radiotherapy. Clin Cancer Res 2004;10:6411-6417.
21. Vale JA, Meredith TJ, Goulding R. Treatment of acetaminophen poisoning. Ann Intern Med 1981;141:394-396.